bioAffinity Technologies (NASDAQ:BIAF) Posts Earnings Results, Misses Estimates By $0.07 EPS

bioAffinity Technologies (NASDAQ:BIAF) issued its quarterly earnings data on Monday. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07), Zacks reports. The company had revenue of $2.20 million for the quarter, compared to analyst estimates of $2.42 million. bioAffinity Technologies had a negative return on equity of 205.09% and a negative net margin of 91.22%. bioAffinity Technologies updated its FY 2025 guidance to EPS.

bioAffinity Technologies Stock Up 319.2 %

Shares of bioAffinity Technologies stock traded up $0.83 during trading hours on Tuesday, reaching $1.09. 488,258,307 shares of the company’s stock were exchanged, compared to its average volume of 2,268,352. The stock has a market cap of $16.99 million, a P/E ratio of -1.33 and a beta of 3.12. The company has a 50 day moving average of $0.57 and a two-hundred day moving average of $1.07. The company has a current ratio of 1.02, a quick ratio of 1.01 and a debt-to-equity ratio of 0.18. bioAffinity Technologies has a fifty-two week low of $0.24 and a fifty-two week high of $3.16.

Wall Street Analyst Weigh In

Separately, Maxim Group reiterated a “hold” rating on shares of bioAffinity Technologies in a report on Tuesday.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.